

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	10066235B4	DE			Alnylam Europe AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

1	Statement of Grounds and Particulars of Opposition to Australian Patent No. 778474, filed by SIRNA Therapeutics, Inc. on August 29, 2008.	<input type="checkbox"/>
2	Statutory Declaration by Martin Edward O'Brien of Spruson and Ferguson in the matter of Opposition to Australian Patent No. 778474, filed by SIRNA Therapeutics, Inc. on August 29, 2008.	<input type="checkbox"/>
3	Notice of Opposition to German Application No. DE 100 66 235, filed by Silence Therapeutics AG on July 10, 2008.	<input type="checkbox"/>
4	Notice of Opposition to German Application No. DE 100 66 235, filed by Sanofi Aventis Deutschland GmbH on July 10, 2008.	<input type="checkbox"/>
5	Notice of Opposition to German Application No. DE 100 66 235, filed by Pfizer Inc. on July 09, 2008.	<input type="checkbox"/>
6	List of Documents in Oppositions to German Application No. DE 100 66 235, filed by Silence Therapeutics AG, Sanofi Aventis Deutschland GmbH, and Pfizer Inc.	<input type="checkbox"/>
7	DAMHA, M. ET AL., "Chapter 5: Oligoribonucleotide synthesis: the silyl-phosphoramidite method," Methods in Molecular Biology 20, Edited by Sudhir Agrawal, Humana Press, NJ: 81-114 (1993).	<input type="checkbox"/>
8	GAIT, M., "Chapter 16: Oligoribonucleotides," Antisense Research and Applications, Edited by Stanley Crooke and Bernard Lebleu, CRC Press, 289-302 (1993).	<input type="checkbox"/>
9	JACKSON, A. L. ET AL., "Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity," RNA Journal, 12(7): 1179-1187 (2007).	<input type="checkbox"/>
10	KOSHKIN ET AL., "LNA (Locked Nucleic Acids) Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Biclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition," Tetrahedron 54: 3507-3630 (1998).	<input type="checkbox"/>
11	KUMAR, M. ET AL., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes," Microbiology and Molecular Biology Reviews, 62(4):1415-1434 (1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

12	PARRISH, S. ET AL., "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," Molecular Cell, 6:1077-1087 (2000). <input type="checkbox"/>
13	SPROAT, B., "Chapter 6: Synthesis of 2'-O-Alkyloligonucleotides," Methods in Molecular Biology 20, Edited by Sudhir Agrawal, Humana Press, NJ: 115-142 (1993). <input type="checkbox"/>
14	SPROAT, B. ET AL., "Chapter 18: 2-O-Alkyloligonucleotides," Antisense Research and Applications, Edited by Stanley Crooke and Bernard Lebleu, CRC Press, 351-362 (1993). <input type="checkbox"/>
15	Various, "Nature Insight: RNA interference," Nature, 431:337-378 (2004). <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.